DUBLIN – Santhera Pharmaceuticals AG, the hottest turnaround story in European biotech this year, raised CHF13.4 million (US$14.8 million) from a sale of treasury shares, as it prepares for a crunch meeting with the FDA to map out a regulatory approval pathway for its Duchenne muscular dystrophy (DMD) drug, idebenone (Catena/Raxone).